content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Stemline Therapeutics, Inc. (STML)

9.80
0.20
(2.08%)
Sep 11, 4:00PM EDT
content_middle

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Previous Close: 
9.60
Open: 
9.65
Bid: 
7.05
Ask: 
10.40
1yr Target Price: 
28.67
Day's Range: 
9.25 - 9.95
52wk Range: 
5.50 - 14.60
Volume: 
176999
Average Daily Volume: 
206084
Market Capitalization: 
229.86M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
23455000M
content_right

Pages